Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single Arm, Multicenter, International Trial of Tisotumab Vedotin (HuMax-TF-ADC) in Previously Treated, Recurrent or Metastatic Cervical Cancer

Trial Profile

A Single Arm, Multicenter, International Trial of Tisotumab Vedotin (HuMax-TF-ADC) in Previously Treated, Recurrent or Metastatic Cervical Cancer

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 27 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tisotumab-vedotin (Primary)
  • Indications Adenocarcinoma; Cervical cancer; Squamous cell cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms innovaTV 204
  • Sponsors Genmab; Seagen
  • Most Recent Events

    • 01 Sep 2022 This trial has been completed in Denmark, according to European Clinical Trials Database record (2 Aug 2022).
    • 23 Jun 2022 Status changed from active, no longer recruiting to completed.
    • 20 Sep 2021 According to a Seagen, Genmab AS media release, based on the data from this trial, the U.S. Food and Drug Administration (FDA) has granted accelerated approval to TIVDAK,for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. TIVDAK is approved under the FDA Accelerated Approval Program based on tumor response and the durability of the response.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top